Navigation Links
Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood

MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X announced today that a report published in the online version of the journal Blood demonstrated that its lead compound, GX15-070 (obatoclax), induced potent cytotoxic responses against patient-derived multiple myeloma tumor cells as a single-agent, and enhanced anti-myeloma effects when used as a combination therapy. GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.

"The ability of GX15-070 to inhibit tumor progression and also enhance the effects of other treatment modalities that often suffer from resistance is encouraging," stated Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "This study describes the novel activity of this compound and supports its therapeutic use in diverse cancer types, including multiple myeloma."

In the preclinical studies, GX15-070 potently inhibited the viability of 15 of 16 human myeloma cell lines (HMCLs), including those resistant to treatment with melphalan (a chemotherapeutic) and dexamethasone (a corticosteroid). Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome inhibitor. Additionally, single-agent studies of the candidate showed that it induced potent cytotoxic responses against patient-derived tumor cells without inducing cytotoxicity to human blood lymphocytes.

Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1 trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. G
'"/>




Page: 1 2

Related medicine technology :

1. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
2. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... WASHINGTON , July 28 Today FRC Action joined 19 pro-life groups ... requesting that Ella, a drug under consideration for FDA approval that can cause abortions but ... , , ... Vice President , made the following comments: , ...
... July 28 Delcath Systems, Inc. (Nasdaq: DCTH ) announced today ... Management Access Conference in New York, NY on Tuesday, August ... Chief Financial Officer, will review the company,s business strategy and recent corporate developments. ... Attendance at this conference is ...
Cached Medicine Technology:FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug 2Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference 2Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... the artery-opening devices , , FRIDAY, May 9 (HealthDay News) ... tiny tools that have extended the lives of millions ... their arteries. , The wire metal mesh tubes, when ... artery and ensure a constant supply of blood to ...
... Week with Signing Bonuses, Raises, SAGINAW, Mich., May ... Saginaw voted overwhelmingly last,night to accept their first labor ... year wage increases of 4 percent., (Logo: ... Week I have had in years. The money is,important, ...
... May 9 Brookdale Senior,Living Inc. (NYSE: BKD ... the Company at the Bank of America 2008 Health ... Mandalay Bay in Las Vegas,Nevada at 4:40 p.m. PDT ... being webcast live and can be accessed through the,Bank ...
... May 9 Tim Booth, a 20-year health,care ... CEO of PrePak Systems,Inc., a turnkey pharmaceutical packaging ... last week by the company,s parent, PrePak,Holdings, which ... and,expansion with financial support from its largest shareholders, ...
... May 9 Almost Family, Inc.,(Nasdaq: AFAM ... nursing,services, today announced that the underwriter of the ... and purchased 262,500,additional shares of common stock at ... the over-allotment, the Company sold 2,512,500 shares,in the ...
... painful periods, glaucoma, depression and many other diseases, ... -- A new class of drugs called vaptans ... of conditions including painful periods, brain hemorrhage, psychotic ... short for vasopressin-receptor antagonists, work by targeting the ...
Cached Medicine News:Health News:Drug-Coated Stents Still Spark Debate 2Health News:Drug-Coated Stents Still Spark Debate 3Health News:Saginaw Nurses Approve First Contract 2Health News:Booth Joins PrePak Systems for Growth, Expansion 2Health News:Almost Family, Inc. Announces Exercise of Over-Allotment Option 2Health News:New Class of Drugs Might Treat Many Conditions 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: